Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN.

Cavazzoni A, La Monica S, Alfieri R, Ravelli A, Van Der Steen N, Sciarrillo R, Madeddu D, Lagrasta CAM, Quaini F, Bonelli M, Fumarola C, Cretella D, Digiacomo G, Tiseo M, Peters GJ, Ardizzoni A, Petronini PG, Giovannetti E.

Oncotarget. 2017 May 23. doi: 10.18632/oncotarget.18087. [Epub ahead of print]

2.

Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility.

Ravelli A, Roviello G, Cretella D, Cavazzoni A, Biondi A, Cappelletti MR, Zanotti L, Ferrero G, Ungari M, Zanconati F, Bottini A, Alfieri R, Petronini PG, Generali D.

Tumour Biol. 2017 Apr;39(4):1010428317695023. doi: 10.1177/1010428317695023. Review.

PMID:
28378631
3.

CDK4/6 inhibitors in HER2-positive breast cancer.

Corona SP, Ravelli A, Cretella D, Cappelletti MR, Zanotti L, Dester M, Gobbi A, Petronini PG, Generali D.

Crit Rev Oncol Hematol. 2017 Apr;112:208-214. doi: 10.1016/j.critrevonc.2017.02.022. Epub 2017 Feb 24. Review.

PMID:
28325261
4.

Anti-proliferative effects of copper(II) complexes with hydroxyquinoline-thiosemicarbazone ligands.

Rogolino D, Cavazzoni A, Gatti A, Tegoni M, Pelosi G, Verdolino V, Fumarola C, Cretella D, Petronini PG, Carcelli M.

Eur J Med Chem. 2017 Mar 10;128:140-153. doi: 10.1016/j.ejmech.2017.01.031. Epub 2017 Jan 23.

PMID:
28182987
5.

Comparison of susceptibility patterns using commercially available susceptibility testing methods performed on prevalent Candida spp.

Cretella D, Barber KE, King ST, Stover KR.

J Med Microbiol. 2016 Dec;65(12):1445-1451. doi: 10.1099/jmm.0.000383. Epub 2016 Nov 1.

PMID:
27902377
6.

Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation.

La Monica S, Madeddu D, Tiseo M, Vivo V, Galetti M, Cretella D, Bonelli M, Fumarola C, Cavazzoni A, Falco A, Gervasi A, Lagrasta CA, Naldi N, Barocelli E, Ardizzoni A, Quaini F, Petronini PG, Alfieri R.

J Thorac Oncol. 2016 Jul;11(7):1051-63. doi: 10.1016/j.jtho.2016.03.006. Epub 2016 Mar 19.

PMID:
27006151
7.

Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines.

Galetti M, Petronini PG, Fumarola C, Cretella D, La Monica S, Bonelli M, Cavazzoni A, Saccani F, Caffarra C, Andreoli R, Mutti A, Tiseo M, Ardizzoni A, Alfieri RR.

PLoS One. 2015 Nov 4;10(11):e0141795. doi: 10.1371/journal.pone.0141795. eCollection 2015.

8.

Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.

Bonelli MA, Cavazzoni A, Saccani F, Alfieri RR, Quaini F, La Monica S, Galetti M, Cretella D, Caffarra C, Madeddu D, Frati C, Lagrasta CA, Falco A, Rossetti P, Fumarola C, Tiseo M, Petronini PG, Ardizzoni A.

Mol Cancer Ther. 2015 Aug;14(8):1916-27. doi: 10.1158/1535-7163.MCT-14-0892. Epub 2015 May 26.

9.

Drug-induced cellular death dynamics monitored by a highly sensitive organic electrochemical system.

Romeo A, Tarabella G, D'Angelo P, Caffarra C, Cretella D, Alfieri R, Petronini PG, Iannotta S.

Biosens Bioelectron. 2015 Jun 15;68:791-7. doi: 10.1016/j.bios.2015.01.073. Epub 2015 Feb 7.

PMID:
25687585
10.

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.

Cretella D, Saccani F, Quaini F, Frati C, Lagrasta C, Bonelli M, Caffarra C, Cavazzoni A, Fumarola C, Galetti M, La Monica S, Ampollini L, Tiseo M, Ardizzoni A, Petronini PG, Alfieri RR.

Mol Cancer. 2014 Jun 5;13:143. doi: 10.1186/1476-4598-13-143.

11.

Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification.

La Monica S, Caffarra C, Saccani F, Galvani E, Galetti M, Fumarola C, Bonelli M, Cavazzoni A, Cretella D, Sirangelo R, Gatti R, Tiseo M, Ardizzoni A, Giovannetti E, Petronini PG, Alfieri RR.

PLoS One. 2013 Oct 22;8(10):e78656. doi: 10.1371/journal.pone.0078656. eCollection 2013.

12.

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines.

Cavazzoni A, Alfieri RR, Cretella D, Saccani F, Ampollini L, Galetti M, Quaini F, Graiani G, Madeddu D, Mozzoni P, Galvani E, La Monica S, Bonelli M, Fumarola C, Mutti A, Carbognani P, Tiseo M, Barocelli E, Petronini PG, Ardizzoni A.

Mol Cancer. 2012 Dec 12;11:91. doi: 10.1186/1476-4598-11-91.

Supplemental Content

Loading ...
Support Center